On April 12, 2023 Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, reported that it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) (Press release, Microbiotica, APR 12, 2023, View Source [SID1234629999]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Microbiotica will conduct a phase 1b clinical trial to evaluate the safety and tolerability, and initial signs of clinical activity of its live biotherapeutic product, MB097, in combination with KEYTRUDA (pembrolizumab), MSD’s anti-PD-1 therapy, in melanoma patients with primary resistance to an anti-PD-1-containing immunotherapy. Microbiotica will be the study sponsor and MSD will supply KEYTRUDA.
MB097 is an orally administered live biotherapeutic product consisting of a defined consortium of nine bacterial strains designed to enhance the efficacy of immune checkpoint inhibitors (ICIs) such as KEYTRUDA.
The bacterial strains in MB097 were identified by analysing the microbiome of patients in multiple studies of ICIs in melanoma. Microbiotica’s discovery platform facilitates precise, strain-level identification of bacterial signatures associated with clinical response. Moreover, MB097 displayed potent anti-tumour efficacy in combination with ICIs in in vivo tumour models and demonstrated multiple immuno-stimulatory mechanisms in primary human immune cell assays including Cytotoxic T Lymphocyte activation and tumour cell killing in vitro.
Tim Sharpington, CEO of Microbiotica, said: "We are delighted to be working with MSD, a world leader in immuno-oncology. The treatment of patients with advanced melanoma has been revolutionised by ICIs such as KEYTRUDA and there is an opportunity to increase the number of patients who can benefit from these treatments. There is growing evidence that the gut microbiome plays a critical role in determining a patient’s response to ICIs and we believe that MB097, in combination with KEYTRUDA, has the potential to enhance the benefit for patients with advanced melanoma and other difficult-to-treat cancers."
(KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.)